Skip to main content
Top

17-06-2024 | Type 2 Diabetes | Original Article

Efficacy and safety of luseogliflozin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Authors: Reddikumar Reddy Galigutta, P. N. Hasik, Christy Thomas, Krishna Undela

Published in: Endocrine

Login to get access

Abstract

Purpose

Owing to the absence of the most recent evidence on the efficacy and safety of luseogliflozin, our study aimed to conduct a systematic review and meta-analysis of luseogliflozin in patients with type 2 diabetes mellitus.

Methods

A comprehensive search of electronic databases like PubMed, Cochrane CENTRAL, and Google Scholar was performed from the inception to the 31st of August 2023 to identify the randomized controlled trials (RCTs) that examined the glucose and body weight lowering efficacy and safety outcomes of luseogliflozin in comparison with control or other active treatments. The fixed or random-effect model was used based on the heterogeneity identified using the I2 statistic and Cochran’s Q test.

Results

Out of 50 non-duplicate articles identified through database searching, 8 RCTs (11 studies) with 1922 patients were included in this study. The efficacy outcomes like HbA1c (MD: −0.59%; 95% CI: −0.90, −0.29; P < 0.001), FPG (MD: −16.01 mg/dL; 95% CI: −19.46, −12.57; P < 0.001), PPG (MD: −36.63 mg/dL; 95% CI: −43.71, −29.55; P < 0.001) and body weight (MD: −1.66 kg; 95% CI: −2.23, −1.12; P < 0.001) were significantly reduced with luseogliflozin compared to the control group. Regarding the safety outcomes, there was no statistically significant difference between the two groups for hypoglycemia (OR: 1.14; 95% CI: 0.70, 1.84; P = 0.60). However, pollakiuria (OR: 4.08; 95% CI: 1.71, 9.69; P < 0.001) and any ADRs (OR: 2.04; 95% CI: 1.33, 3.14; P < 0.001) were significantly higher in the luseogliflozin group compared to the control.

Conclusion

The current study identified a significant improvement in efficacy outcomes of HbA1c, FPG, PPG, and body weight in the luseogliflozin group. Non-significant safety results may be due to a smaller population size and fewer studies. Hence, long-term multicentric RCTs are needed to identify the safety and efficacy in a diversified population.
Appendix
Available only for authorised users
Literature
2.
go back to reference D.J. Magliano, R.M. Islam, E.L.M. Barr, E.W. Gregg, M.E. Pavkov, J.L. Harding et al. Trends in incidence of total or type 2 diabetes: systematic review. BMJ 366, l5003 (2019)CrossRefPubMedPubMedCentral D.J. Magliano, R.M. Islam, E.L.M. Barr, E.W. Gregg, M.E. Pavkov, J.L. Harding et al. Trends in incidence of total or type 2 diabetes: systematic review. BMJ 366, l5003 (2019)CrossRefPubMedPubMedCentral
3.
go back to reference O.R. Temneanu, L.M. Trandafir, M.R. Purcarea, Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice. J. Med Life 9(3), 235–239 (2016)PubMedPubMedCentral O.R. Temneanu, L.M. Trandafir, M.R. Purcarea, Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice. J. Med Life 9(3), 235–239 (2016)PubMedPubMedCentral
4.
go back to reference Y.A. Domínguez, M. Emiliano, L. Puigi, J.H. Rodríguezi, Contribución de la Epidemiología al estudio de la diabetes mellitus. Rev. Cubana Hig. Epidemiol. 55(2), 46–50 (2017) Y.A. Domínguez, M. Emiliano, L. Puigi, J.H. Rodríguezi, Contribución de la Epidemiología al estudio de la diabetes mellitus. Rev. Cubana Hig. Epidemiol. 55(2), 46–50 (2017)
5.
go back to reference A.E.I. Coria, A.A. Cortés, O.F.R. de la Roche, E.C. Hernández, La Diabetes Mellitus y sus implicaciones sociales y clínicas en México y Latinoamérica Diabetes Mellitus and its Social and Clinical Implications in Mexico and Latin America. Archivos en. Med. Fam. 19(4), 91–94 (2017) A.E.I. Coria, A.A. Cortés, O.F.R. de la Roche, E.C. Hernández, La Diabetes Mellitus y sus implicaciones sociales y clínicas en México y Latinoamérica Diabetes Mellitus and its Social and Clinical Implications in Mexico and Latin America. Archivos en. Med. Fam. 19(4), 91–94 (2017)
6.
go back to reference S. Katayama, M. Hatano, M. Issiki, Clinical features and therapeutic perspectives on hypertension in diabetics. Hypertension Res. 41(4), 213 (2018)CrossRef S. Katayama, M. Hatano, M. Issiki, Clinical features and therapeutic perspectives on hypertension in diabetics. Hypertension Res. 41(4), 213 (2018)CrossRef
7.
go back to reference G. Musso, R. Gambino, M. Cassader, G. Pagano, A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann. Med. 44(4), 375–393 (2012)CrossRefPubMed G. Musso, R. Gambino, M. Cassader, G. Pagano, A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann. Med. 44(4), 375–393 (2012)CrossRefPubMed
8.
go back to reference K. Yamamoto, S. Uchida, K. Kitano, N. Fukuhara, L. Okumura-Kitajima, E. Gunji et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br. J. Pharm. 164(1), 181–191 (2011)CrossRef K. Yamamoto, S. Uchida, K. Kitano, N. Fukuhara, L. Okumura-Kitajima, E. Gunji et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br. J. Pharm. 164(1), 181–191 (2011)CrossRef
9.
go back to reference T.A. Zelniker, S.D. Wiviott, I. Raz, K. Im, E.L. Goodrich, M.P. Bonaca et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31–39 (2019)CrossRefPubMed T.A. Zelniker, S.D. Wiviott, I. Raz, K. Im, E.L. Goodrich, M.P. Bonaca et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31–39 (2019)CrossRefPubMed
10.
go back to reference T. Yamada, M. Wakabayashi, A. Bhalla, N. Chopra, H. Miyashita, T. Mikami et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc. Diabetol. 20(1), 14 (2021)CrossRefPubMedPubMedCentral T. Yamada, M. Wakabayashi, A. Bhalla, N. Chopra, H. Miyashita, T. Mikami et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc. Diabetol. 20(1), 14 (2021)CrossRefPubMedPubMedCentral
11.
go back to reference M. Singh, A. Kumar, Risks Associated with SGLT2 Inhibitors: An Overview. Curr. Drug Saf. 13(2), 84–91 (2018)CrossRefPubMed M. Singh, A. Kumar, Risks Associated with SGLT2 Inhibitors: An Overview. Curr. Drug Saf. 13(2), 84–91 (2018)CrossRefPubMed
12.
go back to reference J.B. McGill, S. Subramanian, Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. Am. J. Cardiol. 124(Suppl 1), S45–S52 (2019)CrossRefPubMed J.B. McGill, S. Subramanian, Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. Am. J. Cardiol. 124(Suppl 1), S45–S52 (2019)CrossRefPubMed
13.
go back to reference A. Tentolouris, P. Vlachakis, E. Tzeravini, I. Eleftheriadou, N. Tentolouris. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int. J. Environ. Res. Public Health. 16, 2965 (2019) A. Tentolouris, P. Vlachakis, E. Tzeravini, I. Eleftheriadou, N. Tentolouris. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int. J. Environ. Res. Public Health. 16, 2965 (2019)
14.
go back to reference R. Pelletier, K. Ng, W. Alkabbani, Y. Labib, N. Mourad, J.M. Gamble, Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther. Adv. Drug Saf. 12, 2042098621989134 (2021) R. Pelletier, K. Ng, W. Alkabbani, Y. Labib, N. Mourad, J.M. Gamble, Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther. Adv. Drug Saf. 12, 2042098621989134 (2021)
15.
go back to reference W.L. Bennett, N.M. Maruthur, S. Singh, J.B. Segal, L.M. Wilson, R. Chatterjee et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann. Intern Med 154(9), 602–618 (2011)CrossRefPubMedPubMedCentral W.L. Bennett, N.M. Maruthur, S. Singh, J.B. Segal, L.M. Wilson, R. Chatterjee et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann. Intern Med 154(9), 602–618 (2011)CrossRefPubMedPubMedCentral
16.
go back to reference B. Peene, K. Benhalima, Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes. Ther. Adv. Endocrinol. Metab. 5(5), 124–136 (2014)CrossRefPubMedPubMedCentral B. Peene, K. Benhalima, Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes. Ther. Adv. Endocrinol. Metab. 5(5), 124–136 (2014)CrossRefPubMedPubMedCentral
17.
go back to reference Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, S. Sakai, Y. Samukawa, Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, phase 3 study. Curr. Med Res Opin. 30(7), 1245–1255 (2014)CrossRefPubMed Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, S. Sakai, Y. Samukawa, Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, phase 3 study. Curr. Med Res Opin. 30(7), 1245–1255 (2014)CrossRefPubMed
18.
go back to reference H. Kakinuma, T. Oi, Y. Hashimoto-Tsuchiya, M. Arai, Y. Kawakita, Y. Fukasawa et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J. Med. Chem. 53(8), 3247–3261 (2010) H. Kakinuma, T. Oi, Y. Hashimoto-Tsuchiya, M. Arai, Y. Kawakita, Y. Fukasawa et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J. Med. Chem. 53(8), 3247–3261 (2010)
19.
go back to reference Y. Seino, K. Kaku, N. Inagaki, M. Haneda, T. Sasaki, A. Fukatsu et al. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Endocr. J. 62(7), 593–603 (2015)CrossRefPubMed Y. Seino, K. Kaku, N. Inagaki, M. Haneda, T. Sasaki, A. Fukatsu et al. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Endocr. J. 62(7), 593–603 (2015)CrossRefPubMed
20.
go back to reference R. Hashimoto-Kameda, K.Y. Cho, H. Nomoto, A. Nakamura, K. Omori, S. Nagai, et al. Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). Diabetes Res Clin Pract. 180, 109069 (2021) R. Hashimoto-Kameda, K.Y. Cho, H. Nomoto, A. Nakamura, K. Omori, S. Nagai, et al. Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). Diabetes Res Clin Pract. 180, 109069 (2021)
21.
go back to reference M. Haneda, Y. Seino, N. Inagaki, K. Kaku, T. Sasaki, A. Fukatsu et al. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin. Ther. 38(1), 66–88.e20 (2016)CrossRefPubMed M. Haneda, Y. Seino, N. Inagaki, K. Kaku, T. Sasaki, A. Fukatsu et al. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin. Ther. 38(1), 66–88.e20 (2016)CrossRefPubMed
22.
go back to reference M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021)CrossRefPubMedPubMedCentral M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021)CrossRefPubMedPubMedCentral
23.
go back to reference A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 17(1), 1–12 (1996)CrossRefPubMed A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 17(1), 1–12 (1996)CrossRefPubMed
24.
go back to reference J.A.C. Sterne, J. Savović, M.J. Page, R.G. Elbers, N.S. Blencowe, I. Boutron, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 366, l4898 (2019) J.A.C. Sterne, J. Savović, M.J. Page, R.G. Elbers, N.S. Blencowe, I. Boutron, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 366, l4898 (2019)
25.
go back to reference T. Shibuya, N. Fushimi, M. Kawai, Y. Yoshida, H. Hachiya, S. Ito et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diab. Obes. Metab. 20(2), 438–442 (2018)CrossRef T. Shibuya, N. Fushimi, M. Kawai, Y. Yoshida, H. Hachiya, S. Ito et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diab. Obes. Metab. 20(2), 438–442 (2018)CrossRef
26.
go back to reference M. Sugawara, M. Fukuda, I. Sakuma, Y. Wakasa, H. Funayama, A. Kondo, et al. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study). Diabetes Ther. 14(9), (2023) M. Sugawara, M. Fukuda, I. Sakuma, Y. Wakasa, H. Funayama, A. Kondo, et al. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study). Diabetes Ther. 14(9), (2023)
27.
go back to reference M. Shestakova, B. Kvasnikov, E. Erina, E. Isachenko, A. Andreev, Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial. BMJ Open Diab. Res Care 11(3), e003290 (2023)CrossRefPubMedPubMedCentral M. Shestakova, B. Kvasnikov, E. Erina, E. Isachenko, A. Andreev, Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial. BMJ Open Diab. Res Care 11(3), e003290 (2023)CrossRefPubMedPubMedCentral
28.
go back to reference K. Ejiri, T. Miyoshi, H. Kihara, Y. Hata, T. Nagano, A. Takaishi, et al. Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. J Am Heart Assoc. 9(16), e015103 (2020) K. Ejiri, T. Miyoshi, H. Kihara, Y. Hata, T. Nagano, A. Takaishi, et al. Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. J Am Heart Assoc. 9(16), e015103 (2020)
29.
go back to reference Y. Seino, T. Sasaki, A. Fukatsu, S. Sakai, Y. Samukawa, Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr. Med. Res. Opin. 30(7), 1219–1230 (2014)CrossRefPubMed Y. Seino, T. Sasaki, A. Fukatsu, S. Sakai, Y. Samukawa, Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr. Med. Res. Opin. 30(7), 1219–1230 (2014)CrossRefPubMed
30.
go back to reference Y. Seino, T. Sasaki, A. Fukatsu, H. Imazeki, H. Ochiai, S. Sakai, Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Curr. Med. Res. Opin. 34(6), 981–994 (2018)CrossRefPubMed Y. Seino, T. Sasaki, A. Fukatsu, H. Imazeki, H. Ochiai, S. Sakai, Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Curr. Med. Res. Opin. 34(6), 981–994 (2018)CrossRefPubMed
31.
go back to reference D. Dutta, J. Kadian, K. Mahajan, A. Dhall, M. Sharma, Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis. Diabetes Metab Syndr. 17(3), 102742 (2023) D. Dutta, J. Kadian, K. Mahajan, A. Dhall, M. Sharma, Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis. Diabetes Metab Syndr. 17(3), 102742 (2023)
32.
34.
go back to reference S. Halimi, B. Vergès, Adverse effects and safety of SGLT-2 inhibitors. Diab. Metab. 40(6 Suppl 1), S28–S34 (2014)CrossRef S. Halimi, B. Vergès, Adverse effects and safety of SGLT-2 inhibitors. Diab. Metab. 40(6 Suppl 1), S28–S34 (2014)CrossRef
35.
36.
go back to reference R. Devi, G. Mali, I. Chakraborty, M.K. Unnikrishnan, S. Abdulsalim, Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Postgrad. Med. 129(3), 382–392 (2017)CrossRefPubMed R. Devi, G. Mali, I. Chakraborty, M.K. Unnikrishnan, S. Abdulsalim, Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Postgrad. Med. 129(3), 382–392 (2017)CrossRefPubMed
37.
go back to reference M. Feng, H. Lv, X. Xu, J. Wang, W. Lyu, S. Fu, Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus. Medicine 98(30), e16575 (2019)CrossRefPubMedPubMedCentral M. Feng, H. Lv, X. Xu, J. Wang, W. Lyu, S. Fu, Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus. Medicine 98(30), e16575 (2019)CrossRefPubMedPubMedCentral
38.
go back to reference Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, S. Sakai, Y. Samukawa, Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr. Med. Res. Opin. 30(7), 1231–1244 (2014)CrossRefPubMed Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, S. Sakai, Y. Samukawa, Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr. Med. Res. Opin. 30(7), 1231–1244 (2014)CrossRefPubMed
Metadata
Title
Efficacy and safety of luseogliflozin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Authors
Reddikumar Reddy Galigutta
P. N. Hasik
Christy Thomas
Krishna Undela
Publication date
17-06-2024
Publisher
Springer US
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03925-x
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare